Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07465276 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

Name: Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC — clinical trial record (NCT07465276)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorDana-Farber Cancer Institute

Started2026-03-26

View on ClinicalTrials.gov ↗

Amendment history

2026-03-26

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2026-04-01→confirmed 2026-03-26

Study sitesdetails revised at 2 of 2 sites

2026-03-06

Original filing

Dana-Farber Cancer Institute

287 trials monitored

See 33 trials at risk

Head & Neck Cancer

2,051 trials monitored

See 116 trials at risk

This trial is to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab prior to surgical resection in participants with resectable, high-risk, locoregionally advanced, PD-L1-positive squamous cell carcinoma of the head and neck (HNSCC). The names of the study drugs used in this research study are: * ficerafusp alfa (a type of bifunctional antibody and recombinant fusion protein) * pembrolizumab (a type of monoclonal antibody)

Trial Details

NCT Number	NCT07465276
Lead Sponsor	Dana-Farber Cancer Institute Collaborators: Bicara Therapeutics
Conditions	Head and Neck Squamous Cell Carcinoma (HNSCC), Squamous Cell Carcinoma of the Head and Neck
Enrollment	32 participants
Start Date	2026-03-26
Primary Completion	2028-04-30 (estimated)
Study Completion	2030-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-03-27